Fennec Pharmaceuticals Inc. announced a non-brokered offering of its common shares in Canada at a price of US$7.50 per share.
The offering is expected to raise up to US$5,025,000 in aggregate gross proceeds.
The offering is set to close on November 17, 2025, pending necessary approvals including approval from the Toronto Stock Exchange.
Offering Details
Non-brokered offering of common shares in Canada at US$7.50 per share for existing institutional shareholders.
Regulatory Compliance
Offering made under listed issuer financing exemption under National Instrument 45-106 with no hold period under Canadian securities laws.
Offering Document
Prospective investors in the Canadian offering should review the offering document on SEDARplus and Fennec Pharmaceuticals' website.
- The offering is a strategic move to raise funds for Fennec Pharmaceuticals' operations and development.
- This offering allows existing institutional shareholders to participate in the Company's growth at a set price per share.
- The completion of the offering will depend on subscription agreements with investors and meeting customary closing conditions.
Fennec Pharmaceuticals' private offering in Canada reflects its commitment to strategic fundraising and expansion opportunities within the market.